

Idenix Pharmaceuticals, Inc.

Use of Non-Human Primates (NHPs) in the Discovery and Development of Medicines

Idenix Pharmaceuticals, Inc. (the “Company”) has voluntarily decided to continue its practice of not using great apes (i.e. chimpanzees) in research. For several years the Company has not initiated or funded studies using great apes. The Company continues to not initiate or fund studies using great apes and will not do so in the future. The Company acknowledges that there may be future instances where studies in non-human primates other than great apes (e.g. macaques), may be essential to address efficacy or safety questions but only if no lower order species is appropriate for the purposes of the program.

The Company voluntarily ceased using great apes in research several years ago and adopted this specific policy to provide a tangible demonstration of its commitment to the 3Rs principal (replacement, reduction and refinement) of animal research.

Great apes are gorillas, chimpanzees, orangutans and bonobos. The common chimpanzee has been involved in biomedical research for over three decades. The other great apes have not been used in such research.

Chimpanzees have played a key role in the understanding of many diseases that affect humans; specifically infectious diseases, such as hepatitis C and HIV/AIDs. While the Company recognizes the importance of scientific knowledge derived from past work with the chimpanzees, the Company also acknowledges that the case for using great apes in future biomedical research is less clear than it had previously been understood.